Form 4: Inari Medical CEO Andrew Hykes Sells 3,000 Shares Under 10b5-1 Trading Plan

Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at $50.83 per share on November 20, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Hykes, the President and CEO of Inari Medical, Inc., sold 3,000 shares of common stock on November 20, 2024.
• The sale was executed at a price of $50.83 per share.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on November 13, 2023.
• Following the transaction, Mr. Hykes directly owns 442,310 shares of Inari Medical stock.
• He also indirectly owns 1,550 shares through each of his three children and 1,000 shares through his spouse.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, indicating a neutral sentiment.

Industry Context

This is a routine filing for insider transactions and is common practice for executives who have pre-arranged trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies to manage their personal finances while avoiding potential insider trading issues.
• The sale of 3,000 shares is a relatively small transaction compared to the total holdings of the CEO and is not unusual for executives with significant equity positions.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the stock price given the pre-arranged nature of the transaction.

Key Dates

Keywords

Inari Medical, Andrew Hykes, stock sale, Rule 10b5-1, insider trading, NARI